Skip to main content
Premium Trial:

Request an Annual Quote

Parse Biosciences Partners With Decode Science for Australia, New Zealand Distribution

NEW YORK – Parse Biosciences announced on Tuesday that it has partnered with Decode Science to distribute its single-cell RNA-seq solutions in Australia and New Zealand.

Under the terms of the deal, Decode will provide customer service, technical support, sales and marketing, distribution, and related logistical efforts for the Parse product line — specifically its whole transcriptome, cell fixation, and nuclei fixation kits.

Decode is a distributor of genomic and multiomic products with established relationships at key accounts in the Oceania region, Parse said in a statement.

"We see these markets contributing substantially to our success and found the perfect partner in Decode," said Alex Rosenberg, CEO and cofounder of Seattle-based Parse Biosciences.

Parse Biosciences introduced split-pool combinatorial barcoding to the market earlier this year. The technology is an intrinsically scalable single-cell RNA-seq that does not require a separate hardware purchase, the firm said.

The Parse Bioscience Whole Transcriptome Kit is a single-cell assay that enables the profiling of up to 48 samples and 100,000 cells or nuclei. The Cell Fixation Kit and Nuclei Fixation Kit enable researchers to fix and store suspensions for up to six months.

Parse Biosciences noted that it will also present new capabilities of its platform at this year's American Society of Human Genetics meeting.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.